Champion Innovation at the 7th Dermatology Drug Development Summit
Following 6 FDA approvals of JAK inhibitors and the breakthroughs of the first approved therapies in Prurigo Nodularis, Alopecia Areata and a gene therapy for Dystrophic Epidermolysis Bullosa, interest and investment in dermatology is soaring.
The 7th Dermatology Drug Development Summit returns at the only industry-led summit, gathering 100+ industry frontrunners including LEO Pharma, AbbVie, BMS, GSK, Janssen, Sanofi, Incyte, Dermavant, and many more. Explore the latest trends in targets, modalities and routes of administration, to gain strategic and commercial insights into this competitive landscape.
Gain exclusive access to the full event guide to view the full agenda with 40+ industry-leading speakers.
Join your Dermatology community for three days of unrivalled content, gain tangible exclusive insights into overcoming challenges in preclinical models, addressing safety and toxicity concerns, and segmenting heterogenous disease population.
Ensure your part of these essential progressive conversations to aid our collective effort of harnessing promising novel targets and advancing more durable treatment in the clinic to deliver best-in-class remittive therapeutics for chronic dermatological indications.
Stay at the forefront of innovation in dermatology drug development - secure your pass today
